Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer

Journal of Nippon Medical School

Volumn 75, Issue 1, 2008, Pages 23-27

  Yamada, Takeshi ^a,b   Tanaka, Noritake ^a,b   Yokoi, Kimiyoshi ^a,b   Seya, Tomoko ^a,b   Kanazawa, Yoshikazu ^a,b   Koizumi, Michihiro ^a,b   Ohaki, Yoshiharu ^b   Tajiri, Takashi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

Colon cancer; Dihydropyrimidine dehydrogenase; Orotate phosphoribosyl transferase; Thymidylate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURGERY; COLON ADENOCARCINOMA; COLORECTAL CANCER; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; RECTUM CARCINOMA; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OROTATE PHOSPHORIBOSYLTRANSFERASE; PROGNOSIS; THYMIDYLATE SYNTHASE;

EID: 39749202298     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.75.23     Document Type: Article

References (16)

1. Maughan TS, James RD, Kerr DJ, et al.: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: multicentere randomized trial. Lancet 2002; 359: 1555-1563.
2. Fujii R, Seshimo A, Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 72-78.
3. Johnston PG, Lenz HJ, Leicman CG, et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 1407-1412.
4. Edler D, Blomgren H, Allegra CJ, et al.: Immunohistochemical determination of thymidylate synthase in colorectal cancer-methodological studies. Eur J Cancer 1997; 33: 2278-2281.
5. Ishikawa Y, Kubota T, Otani Y, et al.: Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000; 91: 105-112.
6. Terashima M, Inorida T, Fujiwara H, et al.: Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002; 22: 761-768.
7. Isshi K, Sakuyama T, Gen T, et al.: Predicting 5-FU sensitivity using human colorectal cancer specimens; comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002; 7: 335-342.
8. Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993; 53: 4004-4009.
9. Daiso RB, Beavers TL, Carpenter JT, et al.: Familial deficiency of dihydropyrimidine dehydrogenase. J Clin Invest 1988; 81: 47-51.
10. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH: In Vivo Kinetics of Thymidylate Synthetase Inhibition in 5-Fluorouracilsensitive and -resistant Murine Colon Adenocarcinomas. Cancer Res 1982; 42: 450-456.
11. Salonga D, Danenberg KD, Jhonston M, et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine Phosphorylase. Clin Cancer Res 2000; 6: 1322-1327.
12. Parker WB, Cheng YC: Metabolism and mechanism of action of 5-fluorouracil. Phamacol Ther 1990; 48: 381-395.
13. Ochiai T, Nishimura K, Noguchi H, et al.: Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int J Cancer 2006; 118: 3084-3088.
14. Etienne MC, Cheradame S, Fischel JL, et al.: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J clin oncol 1995; 13: 1663-1670.
15. Fukushima M, Nomura H, Murakami Y, Shirasaka T, Aiba K: Estimation of pathway of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo. Jpn J Cancer Chemother 1996; 23: 721-731.
16. Fujii R, Seshimo A, Kameoka S: Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol 2003; 8: 72-78.